Rnatics

Executive Summary

Rnatics GmbH, a spin-off from the Technical University of Munich, is advancing a novel platform combining AI and RNA therapeutics to develop inhaled therapies for inflammatory and fibrotic lung diseases. The company recently secured a €2.7 million grant from Germany's Federal Ministry of Research, Technology and Space (BMFTR) to support the clinical development of its lead candidate, RCS-21. RCS-21 is a first-in-class inhaled RNA therapeutic designed to address unmet medical needs in chronic respiratory conditions such as idiopathic pulmonary fibrosis (IPF). The grant provides critical non-dilutive funding to advance RCS-21 through IND-enabling studies and initial clinical trials. Rnatics' AI-driven approach accelerates target discovery and RNA design, potentially reducing development timelines and costs. While still in early preclinical stages, the company's innovative modality and targeted delivery method offer a differentiated strategy in the competitive RNA therapeutics landscape. The management team's academic pedigree and the grant validation position Rnatics for potential partnerships and further funding. However, risks include technical challenges of inhaled RNA delivery and limited clinical data. Near-term catalysts include regulatory filing milestones and potential collaboration interest.

Upcoming Catalysts (preview)

• Q4 2026Initiation of GLP Toxicology Studies for RCS-2170% success
• Q2 2027Filing of Clinical Trial Application (CTA/IND) for RCS-2140% success
• Q3 2026Securing Additional Grant or Partnership Funding50% success